Advertisement

Topics

FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps

00:48 EDT 3 Aug 2017 | RTTNews

Today's Daily Dose brings you news about Agile's stock offering; FDA panel's thumbs down for arthritis drug Sirukumab; Theravence's mixed results from its phase IIb study of gastroparesis drug Velusetrag and setback for Puma's Neratinib in the E.U.

Original Article: FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps

NEXT ARTICLE

More From BioPortfolio on "FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps"

Quick Search
Advertisement
 

Relevant Topics

Joint Disorders
A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint causes pain, stiffness, and swelling with ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...